Caseypittman0593

Sickle cell disease (SCD) is a genetic trouble of the hemoglobin synthesis inherited as an autosomal recessive trait, whose prevalence can vary from 5 to 25% in the different parts of the world. It is characterized by the presence of abnormal hemoglobin HbS instead of hemoglobin A. Patients suffering from major forms of SCD present the risk of developing epiphyseal necrosis. Aseptic osteonecrosis of the femoral head (AOFH) caused by ischemia, or bone infarction can affect between 20 and 50% of SCD patients. The femoral head is the most frequent epiphyseal location with a range of 74.6%. AOFH can affect patients at any age, but is mainly detected in men under 50 years. Indeed, a large majority of cases, in a range of 60%, have been diagnosed at an early radiological stage in young adults whose average age varies, in the literature, between 27 and 36 years. A surgical procedure becomes sometimes necessary due to the severity of pain and the functional consequences, frequently following the mechanical collapse of the osteonecrosis area. It is estimated that approximately 25-30% of SCD patients will undergo a total hip arthroplasty before 50y. Although the mortality rate, between 0.2-2.6%, tends to be similar to the general population rate undergoing a prosthetic surgery, the perioperative complications vary from 11.5 to 67%. Here, we clarify the epidemiological data and present an exhaustive update on the different preventive and therapeutic strategies, as well as the perioperative management in patients with an AOFH caused by SCD and risking multiple complications.During the routine dissection of a cadaveric specimen, the left mylohyoid muscle was found to be innervated by both the trigeminal and hypoglossal nerves. This variation was found unilaterally. To our knowledge this dual innervation of the mylohyoid muscle is an extremely rare variation. KN93 The possibility of these variants may lead to clinical consequences such as anesthesia failure and iatrogenic injury during surgical procedures in this region. We discuss this anatomical variation and possible developmental etiologies.Only a few studies published until now have described the fascial-tendinous complex between the temporal and the buccinator muscles, which will be reviewed here. In 1957, the "temporo-buccinator band" (TBB) was described by Gaughran, who gave credit to Hovelaque for its first description in 1914. Zenker coined it in 1955 as the "buccotemporal fascia" (BTF). A buccal extension of the temporal muscle tendon extends from the temporal crest of the mandible to insert within the buccinator muscle, anterior to the pterygomandibular raphe, and posterior to the parotid duct that perforates the buccinator. That tendinous expansion is embedded within the buccotemporal fascia, which is oriented antero-infero-medially and joins the buccopharyngeal fascia, forming the TBB/BTF, above which we find the buccal fat pad. The buccal nerve and artery cross this anatomical structure. The TBB/BTF is an additional layer closing the pterygomandibular space anteriorly, and its knowledge is needed for practitioners performing inferior alveolar nerve blocks.

The aim of this study was to assess the anatomical features of the alveolar antral artery (AAA) in edentulous patients using cone beam computed tomography (CBCT).

The sample consisted of 191 CBCT scans of maxillary sinuses (n=382) of male (n=59) and female (n=132) edentulous patients (age 38-89 years).

The images were analyzed in Dolphin™ 11.9 software. Visualization, location, and diameter of the AAA was registered.

AAA was present in 88.5% of the assessed maxillary sinuses. Bilateral visualization was predominant 77% (P<0.0001). The mean vertical distance from the most anterior part of the AAA to the sinus floor was 7.9±6mm in female patients (both sides) and 12±7.22mm on the right side and 10.9±6.86mm on the left side in males. The mean diameter of the AAA was 1.2±0.7mm on both sides in females. In males, the diameter was significantly (P<0.05) larger 1.5±0.62mm on the right side and 1.4±0.69 on the left side in females.

The AAA had a higher visualization rate, better visualization, and larger diameter when it was present bilaterally in male and female patients.

The AAA had a higher visualization rate, better visualization, and larger diameter when it was present bilaterally in male and female patients.

Active surveillance (AS) of sporadic renal angiomyolipomas (AML) is under-utilised because of an old dogma fearing a life-threatening retroperitoneal hemorrhage when tumour size exceeds 4cm. The objective of this study was to report the outcome of AS in patients with sporadic AML greater than 4cm.

The results of AS in 35 patients managed for sporadic renal AML greater than 4cm were analysed. During AS, tumour growth, occurrence of new symptoms and/or complications, discontinuation of AS protocol, reason for discontinuation as well as subsequent treatment options were reported.

Within a median follow-up of 36months, 16 (46%) patients discontinued AS at the end of the study period (mean follow-up 55±66, median 36months). Patients who discontinued AS were more symptomatic at diagnosis but had similar age, mean tumour size and sex ratio. Active treatment-free survival was 66% at 5years. Retroperitoneal hemorrhage was reported in 3 (8.5%) patients. None of these bleedings required transfusion or monitoring in an intensive care unit. Other reasons for discontinuation were pain (37%), patient preference (19), changes in the radiological appearance of the tumour (19%), and hematuria (6%).

This study showed that AS in AML bearing patients was feasible even in the setting of tumours larger than 4cm. More than 50% of the patients were still on AS at 5 years. Discontinuation of AS was not related to bleeding complications in most cases.

3.

3.

A single immediate instillation of mitomycin C is recommended after a complete transurethral resection of the bladder (TURB) in low- and intermediate-risk patients with NMIBC. Actually, post-TURB instillation is seldom used due to logistical difficulties and surgical contraindications. Our aim was to compare patients with single pre-TURB intra-vesical instillation and patients with a single, immediate post-TURB intra-vesical instillation of mitomycin C.

We performed a multicenter randomized trial between February 17, 2014 and November 24, 2016 (registration number 2012-004341-32). Sixty patients with two or less, primary or recurrent papillary bladder tumors and a negative urinary cytology were planned. Cystoscopy was performed at 3, 6 and 12 months after TURB. Our primary endpoint was disease-free interval. Secondary endpoints were recurrence rate at 3 and 12 months, rate of patients in whom instillation could not be performed and tolerance 1 month after TURB using BCI-Fr score.

Among 35 eligible participants, 20 were randomly assigned in the pre-TURB instillation group and 15 in the post-TURB instillation group.